GLP-1 agonists linked to adverse gastrointestinal events in weight loss patients

doi:10.1136/bmj.p2330

Paper

GLP-1 agonists linked to adverse gastrointestinal events in weight loss patients

Published Oct 9, 2023 · Elisabeth Mahase

BMJ

Q1 SJR score

2

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

The use of glucagon like peptide-1 (GLP-1) receptor agonists for weight loss has been linked to an increased risk of pancreatitis, gastroparesis, and bowel obstruction. 1 A research team from the University of British Columbia, Canada, compared non-diabetic patients using GLP-1 agonists—4144 using liraglutide (Saxenda) and 613 using semaglutide (Ozempic/Wegovy)—with 654 people taking the weight loss agent bupropion-naltrexone. The results, published in a short research letter in JAMA , showed that the use of GLP-1 agonists was associated with increased risk of pancreatitis (adjustedhazardratio,9.09[95%confidenceinterval, 1.25to66.00]),bowelobstruction(HR,4.22[95%CI, 1.02to17.40]),andgastroparesis(HR,3.67[95%CI, 1.15to11.90])butnotbiliarydisease(HR,1.50[95% CI,0.89to2.53]),whencomparedwith bupropion-naltrexone. The incidence of biliary disease was higher for liraglutide (18.6 per 1000 person years), compared with semaglutide (11.7) and bupropion-naltrexone (12.6). For pancreatitis, incidence was 7.9 for liraglutide, 4.6 for semaglutide, and 1.0 for bupropion-naltrexone. “Given

Observational Study

Study Snapshot

GLP-1 agonists for weight loss are associated with increased risks of pancreatitis, bowel obstruction, and gastroparesis, but not biliary disease, compared to bupropion-naltrexone.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

GLP-1 agonists linked to adverse gastrointestinal events in weight loss patients

Sign up to use Study Snapshot

References

Citations

Effects of Very Low-Calorie Diet versus Roux-en-Y Gastric Bypass Surgery on Body Composition in Patients with Obesity

A 12-week very low-calorie diet (VLCD) resulted in similar weight loss and metabolic improvement compared to Roux-en-Y gastric bypass surgery in patients with obesity.